Virios Therapeutics (NASDAQ:VIRI) & ProMetic Life Sciences (OTCMKTS:PFSCF) Critical Comparison

Risk and Volatility

ProMetic Life Sciences has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the S&P 500.

Insider and Institutional Ownership

0.1% of ProMetic Life Sciences shares are owned by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares ProMetic Life Sciences and Virios Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProMetic Life Sciences	$36.55 million	3.49	-$150.73 million	N/A	N/A
Virios Therapeutics	N/A	N/A	-$5.30 million	($0.27)	-11.11

Virios Therapeutics has lower revenue, but higher earnings than ProMetic Life Sciences.

Profitability

This table compares ProMetic Life Sciences and Virios Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProMetic Life Sciences	-894.02%	-3,350.55%	-67.76%
Virios Therapeutics	N/A	-130.33%	-115.00%

Summary

Virios Therapeutics beats ProMetic Life Sciences on 5 of the 8 factors compared between the two stocks.

About ProMetic Life Sciences

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

About Virios Therapeutics

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.